Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 38, 2008 - Issue 10
Submit an article Journal homepage
284
Views
37
CrossRef citations to date
0
Altmetric
Research Article

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

D. K. Walker Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK
,
S. J. Bowers Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK
,
R. J. Mitchell Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK
,
M. J. Potchoiba Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, CT, USA
,
C. M. Schroeder Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, CT, USA
&
H. F. Small Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK
Pages 1330-1339 | Received 13 May 2008, Accepted 21 Aug 2008, Published online: 16 Oct 2008

Citations (37)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Robin DiFrancesco, Getrude Maduke, Rutva Patel, Charlene R Taylor & Gene D Morse. (2013) Antiretroviral Bioanalysis Methods of Tissues and Body Biofluids. Bioanalysis 5:3, pages 351-368.
Read now
Alan Winston & Lucy Garvey. (2009) Clinical Implications of Antiretroviral Pharmacokinetics and Pharmacodynamics in the CNS. HIV Therapy 3:4, pages 361-367.
Read now

Articles from other publishers (35)

Ana Borrajo, Daniel Pérez-Rodríguez, Carlos Fernández-Pereira, José María Prieto-González & Roberto Carlos Agís-Balboa. (2023) Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review. International Journal of Molecular Sciences 24:18, pages 14364.
Crossref
Courtney V. Fletcher, Eugène Kroon, Timothy Schacker, Suteeraporn Pinyakorn, Nicolas Chomont, Suthat Chottanapund, Peeriya Prueksakaew, Khunthalee Benjapornpong, Supranee Buranapraditkun, Nittaya Phanuphak, Jintanat AnanworanichSandhya Vasan & Denise Hsu. (2022) Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression. AIDS 36:7, pages 985-990.
Crossref
Christine Römer. (2021) Viruses and Endogenous Retroviruses as Roots for Neuroinflammation and Neurodegenerative Diseases. Frontiers in Neuroscience 15.
Crossref
Shetty Ravi Dyavar, Nagsen Gautam, Anthony T Podany, Lee C Winchester, Jonathan A Weinhold, Timothy M Mykris, Kayla M Campbell, Yazen Alnouti & Courtney V Fletcher. (2019) Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice. Journal of Antimicrobial Chemotherapy 74:10, pages 2974-2978.
Crossref
Alison C. Savage, Lee M. Tatham, Marco Siccardi, Trevor Scott, Manoli Vourvahis, Andrew Clark, Steve P. Rannard & Andrew Owen. (2019) Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 138, pages 30-36.
Crossref
Lee M. Tatham, Alison C. Savage, Andrew Dwyer, Marco Siccardi, Trevor Scott, Manoli Vourvahis, Andrew Clark, Steven P. Rannard & Andrew Owen. (2019) Towards a Maraviroc long-acting injectable nanoformulation. European Journal of Pharmaceutics and Biopharmaceutics 138, pages 92-98.
Crossref
Alessandro Dalpiaz & Barbara Pavan. (2018) Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?. Pharmaceutics 10:2, pages 39.
Crossref
Charurut Somboonwit, Jose A. Montero, John T. Sinnott & Paul Shapshak. 2017. Global Virology II - HIV and NeuroAIDS. Global Virology II - HIV and NeuroAIDS 405 434 .
Guillaume Martin-Blondel, David Brassat, Jan Bauer, Hans Lassmann & Roland S. Liblau. (2016) CCR5 blockade for neuroinflammatory diseases — beyond control of HIV. Nature Reviews Neurology 12:2, pages 95-105.
Crossref
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S. Utay, Tae Wook-Chun, Surinder Mann, Angela D. Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G. Deeks, Alan Landay, Richard B. Pollard, Christopher J. Miller, Santiago Moreno & David M. Asmuth. (2016) Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLOS Pathogens 12:1, pages e1005381.
Crossref
Katsuyuki MatsushitaHidetoshi Tozaki-SaitohChinami KojimaTakahiro MasudaMakoto TsudaKazuhide InoueSumio Hoka. (2014) Chemokine (C-C motif) Receptor 5 Is an Important Pathological Regulator in the Development and Maintenance of Neuropathic Pain. Anesthesiology 120:6, pages 1491-1503.
Crossref
Maria Luisa Dupuis, Alessandro Ascione, Lucia Palmisano, Stefano Vella & Maurizio Cianfriglia. (2013) Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells. BMC Pharmacology and Toxicology 14:1.
Crossref
Hilda A. Namanja, Dana Emmert, Christine A. Hrycyna & Jean Chmielewski. (2013) Homodimers of the antiviral abacavir as modulators of P-glycoprotein transport in cell culture: probing tether length. MedChemComm 4:10, pages 1344.
Crossref
Christine Eisfeld, Doris Reichelt, Stefan Evers & Ingo Husstedt. (2012) CSF Penetration by Antiretroviral Drugs. CNS Drugs 27:1, pages 31-55.
Crossref
Christoph Boesecke & Sarah L. Pett. (2012) Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Current Opinion in HIV and AIDS 7:5, pages 456-462.
Crossref
Samantha J. Westrop, Graeme Moyle, Akil Jackson, Mark Nelson, Sundhiya Mandalia & Nesrina Imami. (2012) CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection. Molecular Medicine 18:8, pages 1240-1248.
Crossref
David Croteau, Brookie M. Best, Scott Letendre, Steven S. Rossi, Ronald J. Ellis, David B. Clifford, Ann C. Collier, Benjamin B. Gelman, Justin C. Mcarthur, John Allen McCutchan, Susan Morgello & Igor Grant. (2012) Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 26:7, pages 890-893.
Crossref
Lucia Lisi, Antonella Tramutola, Andrea De Luca, Pierluigi Navarra & Cinzia Dello Russo. (2011) Modulatory effects of the CCR5 antagonist maraviroc on microglial pro‐inflammatory activation elicited by gp120. Journal of Neurochemistry 120:1, pages 106-114.
Crossref
Bruce L Gilliam, David J Riedel & Robert R Redfield. (2011) Clinical use of CCR5 inhibitors in HIV and beyond. Journal of Translational Medicine 9:S1.
Crossref
Lamorris M Loftin, Martha Kienzle, Yanjie Yi & Ronald G Collman. (2011) R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies. Journal of Translational Medicine 9:S1.
Crossref
Kevin C. Brown, Kristine B. Patterson, Stephanie A. Malone, Nicholas J. Shaheen, Heather M. Asher Prince, Julie B. Dumond, Melissa B. Spacek, Paris E. Heidt, Myron S. Cohen & Angela D. M. Kashuba. (2011) Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men. The Journal of Infectious Diseases 203:10, pages 1484-1490.
Crossref
N. C. L. Zembruski, G. Buchel, L. Jodicke, M. Herzog, W. E. Haefeli & J. Weiss. (2011) Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. Journal of Antimicrobial Chemotherapy 66:4, pages 802-812.
Crossref
Silvia Sorce, Renier Myburgh & Karl-Heinz Krause. (2011) The chemokine receptor CCR5 in the central nervous system. Progress in Neurobiology 93:2, pages 297-311.
Crossref
Paul Shapshak, Pandjassarame Kangueane, Robert K Fujimura, Deborah Commins, Francesco Chiappelli, Elyse Singer, Andrew J Levine, Alireza Minagar, Francis J Novembre, Charurut Somboonwit, Avindra Nath & John T Sinnott. (2011) Editorial NeuroAIDS review. AIDS 25:2, pages 123-141.
Crossref
Juan Manuel Tiraboschi, Jordi Niubo, Jordi Curto & Daniel Podzamczer. (2010) Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:5, pages 606-609.
Crossref
R. E. Kast. (2010) Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. Journal of Clinical Pharmacy and Therapeutics 35:6, pages 657-663.
Crossref
I. Poizot-Martin. (2010) Antagonistes du CCR5 : apport d’une nouvelle classe d’antirétroviraux dans la prise en charge de l’infection par le VIH. Médecine et Maladies Infectieuses 40:5, pages 245-255.
Crossref
Kevin J. Liner, Michelle J. Ro & Kevin R. Robertson. (2010) HIV, Antiretroviral Therapies, and the Brain. Current HIV/AIDS Reports 7:2, pages 85-91.
Crossref
José das Neves, Mansoor M. Amiji, Maria Fernanda Bahia & Bruno Sarmento. (2010) Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Advanced Drug Delivery Reviews 62:4-5, pages 458-477.
Crossref
SL. PettS. EmeryAD. KelleherDA. Cooper. (2010) Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults. Clinical Medicine Insights: Therapeutics 2, pages CMT.S5420.
Crossref
Aylin Yilmaz, Victoria Watson, Laura Else & Magnus Gisslèn. (2009) Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 23:18, pages 2537-2540.
Crossref
Abhishek Gulati & Phillip M. Gerk. (2009) Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. Journal of Pharmaceutical Sciences 98:7, pages 2317-2335.
Crossref
Lachlan Gray, Michael Roche, Melissa J. Churchill, Jasminka Sterjovski, Anne Ellett, Pantelis Poumbourios, Shameem Sheffief, Bin Wang, Nitin Saksena, Damian F. J. Purcell, Steven Wesselingh, Anthony L. Cunningham, Bruce J. Brew, Dana Gabuzda & Paul R. Gorry. (2009) Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain. Journal of Virology 83:11, pages 5430-5441.
Crossref
Marcus Kaul. (2009) HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Current Opinion in Neurology 22:3, pages 315-320.
Crossref
Olga LatinovicJanaki KuruppuCharles DavisNhut LeAlonso Heredia. (2009) Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. Clinical Medicine. Therapeutics 1, pages CMT.S2365.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.